Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic - insights from the IRONMAN trial
Eur J Heart Fail
.
2024 Oct;26(10):2293-2295.
doi: 10.1002/ejhf.3394.
Epub 2024 Jul 30.
Authors
Matthew M Y Lee
1
,
Mark C Petrie
1
,
John G F Cleland
1
,
Patrick Donnelly
2
,
Mark Francis
3
,
Andrew Hannah
4
,
Alan G Japp
5
,
Catherine Labinjoh
6
,
Ninian N Lang
1
,
Charlotte Manisty
7
,
Colin J Petrie
1
,
Susan E Piper
8
,
Simon G Williams
9
,
Ian Ford
10
,
Paul R Kalra
11
12
13
;
on behalf of the IRONMAN Trial Investigators
Affiliations
1
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
2
South Eastern Health and Social Care Trust, Belfast, UK.
3
Victoria Hospital, Kirkcaldy, UK.
4
University of Aberdeen, Aberdeen Cardiovascular and Diabetes Centre, Aberdeen, UK.
5
Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, UK.
6
Forth Valley Royal Hospital, Larbert, UK.
7
University College London, London, UK.
8
King's College Hospital NHS Foundation Trust, London, UK.
9
University of Manchester, Manchester, UK.
10
Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
11
Department of Cardiology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
12
College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
13
Faculty of Science and Health, University of Portsmouth, Portsmouth, UK.
PMID:
39078467
DOI:
10.1002/ejhf.3394
No abstract available